Endologix takes AAA (abdominal aortic aneurysms) graft to China:
This article was originally published in Clinica
Executive Summary
China has given Endologix the all clear to market its PowerLink stent graft for the minimally invasive treatment of abdominal aortic aneurysms (AAA). The firm has begun shipping the product to physician training centres through its local distributor, Advanced Medical China. "We see a significant opportunity in China with that country's emerging middle class," said Paul McCormick, Endologix' president and CEO. In addition, the Irvine, California firm believes it will be the first to introduce a minimally invasive AAA treatment in Japan, where data from a completed trial of the product have already been filed.